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TACI-Ig Neutralizes Molecules Critical
for B Cell Development and Autoimmune Disease:
Impaired B Cell Maturation in Mice Lacking BLyS
The mature B cell pool consists predominantly of two
functionally and phenotypically distinct populations:
conventional B-2 B cells located in the follicles and mar-
ginal zones (MZ) (Oliver et al., 1997) as well as B-1 B
cells located in peritoneal cavities (Hayakawa and
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ability of TACI-Ig to inhibit the development of collagen- affected by treatment with TACI-Ig versus Hu-Ig or PBS
specific Abs and the incidence of disease in a mouse (Figure 1B). We used Abs to CD21, CD23, IgD, and IgM
model of collagen-induced arthritis (CIA). Last, we pro- to distinguish transitional T1 (IgMCD21) from T2 cells
duced BLyS/ mice to dissect the role of this ligand in and MZ (IgMCD21) B cells (Figure 1). There was a clear
the development of B cells in the preimmune mouse. block in development of both T2 and MZ B cells after
These results provide compelling data indicating the exposure to TACI-Ig. There was a slight increase in newly
importance of factors delivered by specific microenvi- formed (NF) B cells, defined as B220CD21CD23
ronments in the development of normal and autoreactive (Figure 1B). However, there was no incorporation of
B cells. 5-bromo-2-deoxyuridine (BrdU) within the NF B cell
population in the TACI-Ig treated mice (data not shown).
Results We also measured serum Ig levels after 2 and 4 weeks
of treatment with TACI-Ig. The serum levels of IgM
TACI-Ig Treatment of Naive Mice Results in a Specific dropped 2.3-fold after 2 weeks of TACI-Ig treatment,
Loss of Mature B Cell Populations but Has Little but there was no significant drop in IgG compared to
Effect on Other Cell Lineages animals treated with Hu-Ig or PBS (Figure 1C). Similar
We treated naive mice with 100 g of human TACI-Ig, data were obtained from animals treated with TACI-Ig
human IgG (Hu-Ig), or PBS three times a week for a total for 4 weeks (data not shown). The longer half-life of
of 2 weeks to determine its effect on B cells and on other IgG compared to IgM may be responsible for sustained
cells of the immune system. There was no significant levels of IgG in TACI-Ig-treated mice despite their re-
difference in the total cell numbers found in spleen, duced B cell numbers. Alternatively, B cells responsible
thymus, peritoneal exudates (PEC), mesenteric lymph for IgG production in naive mice (including the long-
node (mLN), or BM of mice treated with TACI-Ig (data lived plasma cell pool) may be resistant to TACI-Ig in
not shown). Cells from each tissue were stained with this treatment mode. In addition, an immune response
fluorescently labeled mAbs and analyzed by immunoflu- to the human TACI-Ig protein may result in activation
orescence flow cytometry (FACS) in order to identify events that affect serum Ig. However, we have observed
specific cell lineages in each of these organs (Figure a similar effect on B cell development and Ig production
1A). TACI-Ig treatment had no effect on the percentages in mice treated with murine TACI-Ig (data not shown)
or total numbers of immature and mature thymocytes and in TACI-Ig TG mice (see below).
(data not shown), of mature T cells defined by CD4/CD8
surface expression in the thymus and spleen (data not TG Mice Overexpressing TACI-Ig Have a Severe
shown), or of CD5B220 T cells in mLN, spleen, or PEC Depletion of Transitional T2 and Mature B Cell
(Figure 1A). Spleen monocyte populations identified ei- Populations and Reduced Levels of Circulating Ig
ther as CD5B220 (Figure 1A) or as CD14 cells (data TG mice overexpressing TACI-Ig were produced using
not shown) were not affected significantly by TACI-Ig the VH-E promoter/enhancer to direct expression intreatment. lymphoid cells (Gross et al., 2000). Since normal mice
However, TACI-Ig had a profound effect on the repre-
mount an immune response to human TACI-Ig, we con-
sentation of B cells in peripheral lymphoid organs after
structed TACI-Ig TG mice to study the effects of long-
treatment with TACI-Ig for 14 days. The average percent-
term exposure to the soluble TACI receptor in animalsage of B cells defined as CD5B220 in the mLN of
tolerant to the human protein. We identified expressionuntreated mice was 27.9  1.6% versus 13.4  1.8%
of the transgene in serum from two founder mice (4687in treated mice and dropped from 52.5 3.7% to 36.5
and 4671) by Western blot analysis using polyclonal Abs2.0%, respectively, in the spleen (Figure 1A). There also
to TACI (Figure 2A) and anti-human Fc Ab (data notwas a moderate decrease in the percentage of B-1
shown). The two MW species identified in TG serum(B220CD5) B cells in the PEC of TACI-Ig treated mice,
represent active proteolytic fragments of TACI-Ig. Thedropping from 38.3 2.1% in the control group to 29.5
levels of TACI soluble receptor were found to be 0.6 1.4% in the TACI-Ig treated mice (Figure 1A). The BM
0.075 mg/ml in mice from line 4687 (Figure 2B) detectedwas analyzed to determine the effect of TACI-Ig treat-
by ELISA. Serum levels of both IgM and IgG were de-ment on stem cell populations and on B cell precursors.
pressed in the TACI-Ig TG mice. There was an averageThere was no apparent change in the fraction of BM-
2.5-fold drop in serum IgM and a 5-fold drop in serumderived stem cells in the B220IgMIgD population
IgG levels measured in 20 TG mice from line 4687 (ages(Figure 1A). In addition, B220 pre- and pro-B cells
9–23 weeks) compared to average values measure in 7(B220IgMIgD) and immature B cells (B220IgM
littermate controls of similar age (Figures 2C and 2D).IgD) were not altered by TACI-Ig treatment. However,
Thus, chronic expression of TACI-Ig in the TG mice leadsthere was a clear decrease in the mature recirculating B
to a decrease in IgG levels that was not observed incell population (B220IgMIgD) in the BM. The average
normal adult mice treated for a short time with proteinpercentage of these cells dropped from 10.5  3.2% in
(Figure 1).the group treated with Hu-Ig to 5.6  1.3% in the TACI-Ig
The total numbers of cells comprising the peripheraltreatment group (Figure 1A).
lymphoid compartments were determined in the TACI-
Ig TG mice and littermate controls (Figure 2E). TotalTACI-Ig Specifically Blocks the Development of B
splenocyte numbers in adult TACI-Ig TG mice were 1.7-Cells at the Transition from T1 to T2 and the
fold lower than splenocyte numbers in control mice (Fig-Development of MZ B Cells in the Spleen
ure 2E, p  0.0004). In addition, there was a statisticallyWe examined the numbers of splenic B cell populations
(defined as B220) to determine which populations were significant decrease (p  0.0006) in the numbers of B-1
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Figure 1. Mature B Cells and Serum IgM Levels Are Reduced in TACI-Ig-Treated Mice
Five BALB/c mice were treated three times/week for 14 days with PBS (data not shown), 100 g of TACI-Ig, or Hu-Ig control protein. On the
14th day, thymus, mLN, spleen, BM, and PEC were collected, stained with fluorescently labeled mAbs to a variety of cell surface markers,
and analyzed by flow cytometry.
(A) Representative profiles are shown for mLN, PEC (lymphocyte-gated), BM, and whole or B220 spleen. PEC, mLN, and spleen were stained
with anti-CD5 and anti-B220 mAbs to distinguish T and B cells. BM cells were stained with mAbs to IgM, IgD, and B220 and gated on B220
lymphocytes. Splenic B cell subsets were identified as described in the text by simultaneously staining for CD21 and IgM to distinguish T1,
T2/MZ, and M B cells, or for CD21, CD23, and B220 to identify NF, FO, and MZ B cells within the B220 population.
(B) BALB/c mice were treated as described in (A) with PBS (open bars), Hu-Ig (hatched bars), or TACI-Ig (solid bars). Comparisons of the
number of B cells in T1, T2/MZ, and M (left panel), and NF, FO, and MZ (right panel) for each group of mice are shown, and the cell surface
markers used to define each subset are indicated. Error bars depict the standard deviation from the mean of each group; asterisks denote
numbers whose p values (as calculated by Student’s unpaired t test) were significantly different than the other two groups (p  0.05).
(C) The levels of IgM (left panel) and IgG (right panel) in the serum of the mice described in (B) were assessed either before (open bars) or
after (solid bars) 14 days of the indicated treatment.
and B-2 PEC in the TG mice (Figure 2E). However, the and mature thymocytes defined by CD4 and CD8 ex-
pression, and the ratios of CD4 and CD8 T cells areTACI-Ig TG mice have normal numbers of cells in the BM,
thymus, and mLN compared to control mice (Figure 2E). normal in spleen, mLN, and thymus (data not shown).
The average percentage of B-2 cells was reduced fromThe thymus, mLN, spleen, BM, and PEC were isolated
from ten TG mice and five non-TG. Cell populations were 28.6  2.9% to 3.9  1.6% in the mLN (CD19), from
56.1  6.2% to 19.9  6.2% in the spleen (B220CD5),analyzed by FACS to characterize the effect of the TACI-
Ig transgene on the developing immune system. Repre- and from 37.2  6.9% to 7.8  3.1% in the peritoneum
(B220CD5) (Figure 3A). There was also a loss of B-1sentative FACS analyses of these populations are shown
in Figure 3A, and a detailed quantitative analysis of total cells in the peritoneum, dropping from 14.5  3.4% in
non-TG mice to 4.3  2.8% in mice expressing TACI-cell numbers is shown in Figure 3B. The thymus of TACI-
Ig TG mice contains normal percentages of immature Ig, representing a 3.5-fold drop in the total number of
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Figure 2. TACI-Ig TG Mice Have Reduced
Numbers of Splenocytes, PEC, and De-
creased Levels of Serum Ig
(A) 10 ng TACI-Ig (left lane) and 2.5l of serum
from non-TG mice (#1 and #2) and two inde-
pendent TACI-Ig TG founders (#4687 and
#4671) were resolved on a NuPage MES gel
(4%–12%), immunoblotted with TACI-spe-
cific rabbit polyclonal Abs, detected with
HRP-conjugated anti-rabbit Ig, and devel-
oped using chemiluminescence. The pre-
dicted MW from the TACI-Ig TG construct is
smaller than the MW of the TACI-Ig standard
used in the Western blot. Partial proteolysis
of TACI-Ig was observed in serum from both
founders #4687 and #4671, resulting in two
MW species approximately 46 and 44 kDa.
(B) TACI-Ig serum levels were determined by
ELISA for offspring of TACI-Ig TG founder
#4687. Values represent the average TACI-Ig
concentration in the serum of four non-TG
and four TACI-Ig TG mice (8–10 weeks of
age). Error bars depict the standard deviation
from the mean of each group; the asterisk
indicates a statistically significant difference
between the two groups (p 0.05). The levels
of (C) IgM and (D) IgG in serum from non-TG
mice (open bars) and offspring of TACI-Ig TG
founder #4687 (solid bars) were determined
by ELISA. Values represent the average of 7
non-TG and 20 TACI-Ig TG mice, from 9–23
weeks of age; statistical significance of the
data was determined as in (B).
(E) Cell suspensions from spleen, thymus,
BM, mLN, and PEC were prepared from non-
TG and TACI-Ig TG mice and numbers of try-
pan blue-excluding live cells were counted.
The average total cell number in each organ/
compartment of five non-TG (open bars) and
ten TACI-Ig mice (solid bars) is shown.
B-1 cells (Figure 3). This suggests that the B-1 cells may important for the development of both these B cell popu-
lations.be dependent on BLyS and/or APRIL for their survival
or development (see Discussion). There is also a dramatic decrease in the T2 B cell
population and mature FO B cell populations, whereasThere is a clear loss of mature IgMlowIgD (Fraction I),
as well as the less mature Fractions II (IgMIgD) and the numbers of T1 B cells are relatively unaffected in
TACI-Ig TG mice (Figure 3B). There is an increase inIII (IgMIgDlow) (Hardy et al., 1982) B cells in the spleen
of non-TG versus TACI-Ig TG mice (Figure 3). There is CD21dullCD23 B cells in the spleen of TACI-Ig TG mice
(Figure 3B). This may represent a novel transitional pop-also a specific arrest in the development of both T2 and
MZ B cells (CD21 IgM), decreasing from 11.7  3.2% ulation or alternatively a downmodulation of CD21 on
the surface of the FO B cell population. BM from TACI-in control mice to 1.6  0.6% in mice expressing TACI-
Ig, whereas the T1 transitional B cells remain unaffected Ig TG mice contains slightly lower numbers of IgMIgD
immature B cells (Figure 3B). Remarkably, despite the(Figure 3A). It should be noted that “Fraction III” (Hardy
et al., 1982) and the T1 cell population are not equivalent, substantial loss of mature B cells, there is only a subtle,
but significant, decrease in the numbers of CD4 andsince Fraction III actually consists of a mixture of NF/
T1, MZ, some B-1, and other activated B cells. Thus, CD8 T cells in the spleen and mLN of TACI-Ig TG mice
(Figure 3B; data not shown).there is no discrepancy in the observation that the num-
ber of Fraction III B cells drops dramatically in the TACI-
Ig TG mice, while the numbers of T1 B cells are compara- TACI-Ig Inhibits the Progression of Disease and
Autoantibody Titers in a Mouse Model of CIAble to those in the non-TG controls (Figure 3B). There
is also a distinct block in the development of MZ B cells There are elevated levels of BLyS in the serum of pa-
tients with RA (Cheema et al., 2001) and SLE, correlatingin the TACI-Ig TG mice (Figure 3A). Given the compelling
similarities between B-1 and MZ B cells (Martin and with elevated levels of autoreactive Abs (Zhang et al.,
2001). Therefore, BLyS represents an appropriate targetKearney, 2000a), our data suggest that a common set
of factors, which likely include BLyS and/or APRIL, are for intervention in autoimmune diseases characterized
BLyS Is Required for B Cell Development
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Figure 3. The B Cell Compartment in TACI-Ig TG Mice Is Dramatically Altered Relative to That of Non-TG Mice
(A) Cell suspensions from non-TG (left columns) or TACI-Ig TG (right columns) BM, mLN, spleen, and PEC were stained as described in Figure
1 and analyzed by flow cytometry, and splenic B cell subsets were identified as described in Figure 1. Splenocytes were also costained with
anti-IgD and anti-IgM Abs to distinguish Fractions III (FrIII), II (FrII), and I (FrI) as described in the text.
(B) The average number of the following cell types from five non-TG (open bars) or ten TACI-Ig TG (solid bars) mice are plotted (upper panels):
total or CD19 B cells in the mLN; B-2, B-1, and T cells in the PEC; or pro B (B220lowCD43), pre B (B220lowCD43IgM), immature B, and
mature recirculating B cells in the BM. The average number of each splenic B cell subset, as well as the total number of CD4 and CD8
splenic T cells are also plotted (lower panels). Error bars represent the standard deviation from the mean; asterisks denote statistically
significant differences (p  0.05).
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by elevated levels of autoantibodies that contribute to and 2.2) or Hu-Ig treated mice (6.2 and 1.3) (Figure 4G).
Overall, these results indicate a reduction in disease indisease pathology. The ability of TACI-Ig to suppress
the development of Abs to foreign antigens indicates mice receiving TACI-Ig. Specifically, the articular carti-
lage in the TACI-Ig treated group generally was undam-that it might be useful in suppressing the development
of autoreactive Abs and disease in the CIA model of RA. aged, and there was less inflammation and hypertrophy
of the synovium (Figure 4G). In addition, the TACI-Ig-We treated mice with TACI-Ig, Hu-Ig or PBS three
times a week, i.p., for 3 weeks. In the prevention mode, treated group had fewer inflammatory cells in the soft
tissues surrounding the joints (Figure 4G).treatment was initiated 7 days prior (day 7) to the
second collagen injection (day 0), when there are already
increased serum titers of anti-collagen Abs and few The Phenotype of BLyS/ Mice Demonstrates
that BLyS Is Required for the Developmentovert signs of disease (Figures 4A–4C). Qualitative clini-
cal scores of disease were assessed daily for all four of B-2 B Cells but Not B-1 Cells
To elucidate the involvement of BLyS in B cell differenti-paws (scale 0–3). The average paw score and the per-
centage of animals with established disease were re- ation and homeostasis, we produced BLyS-deficient
mice by targeted gene disruption. The targeting strategyported for each group. In addition, serum samples were
tested for circulating anti-collagen Abs at day –3, day was designed to delete sequences encoding amino
acids 286 of BLyS, encompassing the cytoplasmic tail14, and day of sacrifice (Figure 4C).
Prophylactic administration of TACI-Ig delayed the and transmembrane domain (Figure 5A). BLyS/mutant
offspring were found to be present at the expected Men-onset and lowered the severity of inflammation in the
TACI-Ig treatment group (Figure 4A). No disease was delian ratio (23%: 54%: 23%, respectively; n  75).
BLyS/ animals were viable, appeared outwardly nor-observed until after day 18, 4 days after dosing was
stopped. In addition, TACI-Ig decreased the percentage mal, and showed no obvious differences in size, behav-
ior or reproductive ability. No BLyS expression was de-of animals that developed established disease com-
pared to mice treated with Hu-Ig or PBS (Figure 4B). tected in adult lung or spleen isolated from BLyS/
mice (Figure 5C; data not shown), demonstrating that aTACI-Ig suppressed the development of anti-collagen
Abs on day 14 (3 weeks after treatment was initiated) null allele had indeed been generated.
The average levels of serum IgG and IgM were re-and on day of sacrifice, compared with the Hu-Ig and
PBS control groups (Figure 4C). duced 4.6- and 3.9-fold, respectively, in BLyS / mice
compared to Ig levels in WT mice (Figure 5D). Cell popu-Administration of TACI-Ig 7 days after the second
dose of collagen more closely represents a therapeutic lations in the spleen, thymus, PEC, mLN, and BM were
characterized by FACS in ten BLyS/ mice and ninemode of treatment. At this time, anti-collagen Abs are
elevated, and inflammation was present in an average age-matched control mice, ranging from 6 to 16 weeks
of age. Total cell numbers in different lymphoid compart-of 52% of the animals (data not shown). Administration
of TACI-Ig at this stage inhibited the progression of ments were calculated (Table 1) and representative
FACS of specific cell subsets are shown (Figure 6). Thedisease, reflected in lower average paw scores (de-
creased severity of inflammation) (Figure 4D) and in the total numbers of cells isolated from thymus, BM, and
PEC from BLyS/ mice were not significantly differentdecreased percentage of animals with established dis-
ease (Figure 4E). The serum Ab titers to collagen were than numbers obtained from wild-type mice (Table 1).
However, the total numbers of cells found in spleen andslightly decreased in the TACI-Ig treatment group at day
14, 1 week after the start of treatment, and decreased LNs of BLyS/ mice were reduced compared to WT
mice, from 199.7  36.6 ( 106) to 75.5  24.0 ( 106)further in serum samples taken on day 28 and day of
sacrifice (Figure 4F). Immunohistochemical staining of in the spleen and from 28.7  3.2 ( 106) to 9.9  0.5
( 106) in the mLN.spleen cryosections revealed that splenic architecture
of TACI-Ig treated mice was normal but contained fewer The BLyS/ mice contained normal thymocyte popu-
lations defined by CD4 and CD8 (data not shown) andFO B cells (data not shown).
Histological assessment of arthritis in interphalangeal normal numbers of CD3 peripheral T cells in the spleen
(Table 1) and mLN (data not shown), indicating thatjoints of paw sections revealed that mice receiving TACI-
Ig had lower average paw and joint scores (3.3 and 0.5, BLyS/ T cells can differentiate and populate the periph-
ery. However, it remains to be determined whether theserespectively) compared to the PBS-treated mice (11.3
Figure 4. TACI-Ig Treatment Before or during the Onset of CIA Prevents the Production of Anti-Collagen Abs and Dramatically Reduces the
Severity of the Disease
(A–F) Mice were immunized with type II chick collagen emulsified in CFA on day –21 and IFA on day 0. Treatment was initiated on day –7 (A,
B, and C) or on day 7 (D, E, and F). Fifteen mice per group received PBS (circles) or 100 g of either Hu-Ig (triangles) or TACI-Ig (squares)
i.p. three times/week for 3 weeks. Arthritic lesions for each paw were graded daily using a scoring system of 0–3 (see Experimental Procedures),
and mice were identified as diseased if the score of one paw was at least 2. The average paw score was calculated for each group (A and
D), and the average number of animals with disease was determined (B and E). (C and F) Collagen-specific Abs were measured in serum
samples drawn on the days indicated. The results were reported as geometric mean and standard error of the OD490 values from ELISAs
detecting collagen-specific Abs.
(G) Histopathology of the joints from four paws was assessed on six mice from each treatment group, sacrificed 7 days after being diagnosed
with disease. Representative sections stained with H&E are shown from the PBS-, Hu-Ig-, and TACI-Ig-treated groups, as indicated. Arrowheads
indicate the surface of the articular cartilage. Pathology scores of 0–4 were assigned for paws and digits (see Experimental Procedures) of
six mice in each group (table); mean scores and the standard deviation from the mean are reported.
Immunity
296
Figure 5. BLyS-Deficient Mice Generated by Gene Disruption Have Reduced Levels of Circulating Ig
(A) A partial restriction endonuclease map of the wild-type mouse BLyS locus (top), structure of the BLyS targeting vector (middle), and
resulting homologous recombinant allele (bottom) are shown, in which sequences encoding amino acid residues 2–80 were deleted and
replaced with a lacZ gene and neo selectable marker (IRES	GAL/MC1neo). Exons 1 and 2 of BLyS are indicated by black boxes, and exon
3 is not shown. ES cells and animals were genotyped by genomic Southern blotting using probes A and B (horizontal black bars) to confirm
the recombinant 5 and 3 junctions, respectively. The expected sizes of BglII-digested bands (horizontal dashed lines) representing the wild-
type (WT) allele and BLyS null allele was detected by Southern hybridization with 3 probe B. PCR primer pairs used to detect the WT and
neo alleles are indicated by opposing black arrows and were used to genotype most of the progeny.
(B) Genomic Southern blot analysis using 3 probe B of BglII-digested tail DNA from BLyS/ (/) and BLyS/ (/) mice derived from
breeding BLyS/ (/) mice.
(C) Northern blot analysis of poly A RNA isolated from the lungs (2 g/lane) of BLyS/ (/) and BLyS/ (/) mice. Hybridization was
performed with a BLyS exon 3-specific radioactive probe (upper panel). As a control for equal RNA loading, blots were stripped and rehybridized
with a mouse actin probe (lower panel).
(D) The levels of IgM (left panel) and IgG (right panel) in the serum of WT mice (open bars) and BLyS/ (solid bars) were assessed by ELISA.
Values represent the average of five WT and nine BLyS/ mice, from 10–14 weeks of age; asterisks denote statistically significant differences
(p  0.05).
are normal functional T cells. The expression of TACI effector T cells. The numbers of CD44CD62Lmemory/
effector T cells were reduced from 13.6  5.6 ( 106)on the surface of activated T cells (Bram et al., 2000)
potentially implicates the ligands for TACI in the pro- in WT mice to 6.6  2.2 ( 106) in BLyS/ mice (Table
1). This represents a small but statistically significantcesses of T cell stimulation and/or differentiation into
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Table 1. Peripheral B Cell Numbers Are Dramatically Reduced in BLyS/ Mice
Cell Counts (106)a
WT BLyS/ p valueb
Thymus 161.1  100.7 166.3  43.7 0.94
Spleen 199.7  36.6 75.5  24.0 0.0001
mLN 28.7  3.2 9.9  0.5 0.0002
BMc 9.6  2.6 9.8  3.1 0.87
PEC 2.2  1.2 1.5  0.4 0.19
Spleen B (B220)d
T1 9.0  4.6 10.0  4.7 0.58
T2/MZ 19.2  14.5 0.6  0.6 0.0002
Mature 68.0  18.7 3.4  1.2 0.0001
NF 12.4  3.3 16.8  7.1 0.11
FO 81.7  28.2 0.5  0.2 0.0001
MZ 11.6  6.7 0.5  0.3 0.0001
Spleen T (CD3)d
All T 77.7  12.6 48.8  17.0 0.062
Naive T 45.7  17.0 35.5  13.7 0.0046
Memory T 13.6  5.6 6.6  2.2 0.0018
PEC
B-2 0.16  0.15 0.04  0.03 0.07
B-1 0.17  0.17 0.07  0.04 0.18
BM (B220)
IgMD 4.5  0.7 5.2  1.5 0.26
Immature IgMD 2.3  0.7 2.4  0.7 0.75
Mature IgMD 0.8  0.2 0.2  0.05 0.0001
a To obtain the number of cells in each subpopulation, the total number of trypan blue-excluding cells was multiplied by the percentage of
cells in each subset, as determined by FACS analysis (Figure 6). Values represent the mean (106) and standard deviation from the mean
of data from 7-9 WT and 7-10 BLyS/ mice.
b p values were calculated using Student’s unpaired t-test; values deemed statistically significant (p  0.05) are in boldface.
c BM cell counts represent the number of cells isolated from one hindleg femur.
d B and T cell subsets are defined as described in Figure 6.
(p  0.0018) decrease in effector T cells in mice lacking secting the biological effects mediated by this family of
proteins. Exemplifying this complexity is the associationBLyS.
B cell development is blocked at the transitional T1 of BLyS and APRIL with two known receptors, TACI and
BCMA (Gross et al., 2000; Marsters et al., 2000) andstage (CD21IgM) in BLyS/ mice such that virtually
no T2, MZ, or FO B cells are present (Table 1; Figure 6). recent evidence for a potential new receptor for these
molecules (our unpublished data). Both BLyS and APRILNF B cells are present in normal numbers in the spleens
of BLyS/ mice and represent the majority of B cells in are capable of stimulating B cells in vitro (Moore et al.,
1999; Schneider et al., 1999; Yu et al., 2000), and BLySthe spleen (Table 1). Immunohistochemical staining of
spleen cryosections from 4 BLyS/ mice revealed nor- can expand B cell populations in vivo (Gross et al., 2000;
Mackay et al., 1999), whereas APRIL has been shownmal splenic architecture in BLyS/ mice. Metallophilic
macrophages were normal, but there was an increase to costimulate T cells (Yu et al., 2000) and to enhance
the survival of some tumors (Hahne et al., 1998). Severalin CD3 T cells and reduction of FO B cells (data not
shown). experiments have demonstrated an association be-
tween elevated levels of circulating BLyS and autoim-Analysis of the BM revealed that BLyS/ mice have
normal numbers of pre/pro and immature B cells but mune disease, including SLE in mice (Gross et al., 2000)
and humans (Zhang et al., 2001) and RA in humansreduced numbers of mature recirculating B cells (Table
1; Figure 6). We compared the percentages and total (Cheema et al., 2000), whereas APRIL has been impli-
cated in cancer (Ware, 2000). We report here experi-numbers of B-1 cells in the peritoneum of WT and
BLyS/ mice (Figure 6; Table 1). The average percent- ments that further characterize the biology associated
with this family of proteins. We have used TACI-Ig, aage of B-1 cells defined as B220lowCD5low were not dra-
matically different in BLyS/ mice compared to percent- protein capable of neutralizing both BLyS and APRIL,
to understand the role of these ligands in normal andages in WT mice (32.6  9.1% and 28.0  9.5%,
respectively). The total numbers of B-1 B cells in the perito- diseased mice. We have also produced BLyS-deficient
mice to elucidate the biology of this ligand and its roleneum of BLyS/ mice were not signficantly different from
WT mice, while the peritoneal B-2 cell population in in the developing immune system.
The introduction of TACI-Ig to preimmune micethese mice is severely reduced (Table 1; Figure 6).
achieved either by treatment with soluble protein or by
overexpression of TACI-Ig as a transgene, led to a dis-Discussion
ruption in B cell development without substantially af-
fecting other cell populations (Figures 1–3). This sug-The growing number of TNF ligands and receptors with
multiple partners has added to the complexity of dis- gests that either BLyS or APRIL is made constitutively
Immunity
298
Figure 6. BLyS-Deficient Mice Lack Mature Splenic B Cells but Have Apparently Normal Populations of Peritoneal B-1 Cells and Immature
BM B Cells
Splenocytes, PEC, and BM cells from ten 6- to 16-week-old BLyS/ mice and nine age-matched wild-type (WT) control mice were stained
with mAbs to the cell surface molecules indicated and analyzed by flow cytometry as described in Figures 1 and 3. Splenocytes were also
stained with mAbs to CD44, CD62L, and CD3 and gated on CD3 lymphocytes to determine the relative distribution of naive (CD44CD62L),
“activated”(CD44CD62L), and memory (CD44CD62L–) T cells. Representative plots for whole lymphocyte-gated, B220, and CD3 spleen,
lymphocyte-gated PEC, and B220 BM are shown. The percentages of cells in each quadrant or region are indicated.
and is required for the development and homeostasis the lack of perturbation of these cells in the BM of
BLyS/ mice, suggests that B cells will repopulate theof the peripheral B cell pool.
Characterization of splenic B cells in both TACI-Ig- periphery after TACI-Ig is cleared from the animal.
Recent experiments have shown that BLyS can acttreated or TG mice revealed a specific arrest in B cell
development at the immature transitional T1 stage (Fig- as a survival factor for B cells. One group demonstrated
that BLyS is sufficient to prolong the survival of naiveures 1 and 3). The number of T1 cells in these mice was
unaffected by TACI-Ig but there was a dramatic loss of resting B cells in vitro by attenuating apoptosis, inde-
pendent of antigen stimulation (Do et al., 2000). AnotherT2, mature, and MZ B cells in the spleen. These results
suggest that the factors neutralized by TACI-Ig are re- group showed that BLyS preferentially induces the sur-
vival in vitro of splenic immature T2 B cells but not T1quired to drive B cell differentiation at the T1 stage or
are required to sustain mature B cell populations. The or mature cells (Batten et al., 2000). Our data support a
role for BLyS in the differentiation from T1 to T2 but weunique population of splenic CD21dullCD23 B cells iden-
tified in TACI-Ig TG mice may represent a novel transi- cannot rule out a role for BLyS as a survival factor for
the T2 population.tional B cell population. Alternatively, CD21 could be
downmodulated as a result of exposure to high levels A functional BCR is absolutely required for the devel-
opment of B cells, but a variety of other receptors andof TACI-Ig in the TG mice. Analysis of the lymphoid
compartment of BLyS/ mice demonstrates the require- signals from the microenvironment also provide essen-
tial cues necessary for proper B cell development (Loderment for this ligand in the development of mature B cell
populations. The block in B cell differentiation past the et al., 1999). B cell maturation in mice deficient for the
BCR signaling element Ig
 (mb1c/c) is arrestedT1 stage observed in TACI-Ig TG mice is even more
pronounced in spleens from BLyS/ animals. The total somewhat before or just at the T1 stage in the spleen
(Torres et al., 1996). The T1 population in these mice isnumber of splenic T1 cells is the same in BLyS/ and WT
mice, but the mature, T2, and MZ B cells are completely 20% of normal, indicating the need for BCR signaling
during the differentiation from immature BM-derived Babsent in spleens of mutant mice (Figure 6; Table 1).
The arrest in B cell development is restricted to the cells to the transitional T1 stage. B cells from Syk/
mice migrate from the BM to the spleen but do not enterperipheral mature and immature B cell populations. Nor-
mal B cell precursor populations (pro- and pre-B cells) into the primary follicle and instead remain in the red
pulp and outer PALS (Turner et al., 1995). Pyk-2-deficientare present in BM isolated from TACI-Ig treated mice
and TACI-Ig TG mice (Figure 3). This observation, and mice do not develop MZ B cells but have normal B-1
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and FO B-2 cells (Guinamard et al., 2000). Taken to- Abs and therefore may be useful in suppressing patho-
gether, these studies demonstrate the key roles played genic autoantibodies in disease.
by specific molecules during B cell development. The The mature long-lived pool of B cells is composed of
phenotype of BLyS/ mice indicates that this factor is the B-1 B cell subset, MZ B cells, and mature B-2 B
important for the T1 to T2 transition and may represent cells that recirculate among the follicles. The long-lived
one of the factors supplied by the microenvironment pool of B-2 B cells is derived from NF B cells that mature
supporting these B cell populations. through the transitional stage in the spleen. Alterna-
TACI-Ig treatment has little effect on T lineage cells tively, mature B cells can migrate to more static com-
or myeloid cell populations in the spleen, mLN, and PEC partments including the MZ B cells or peritoneal cavity
(Figure 1; data not shown). The high levels of TACI-Ig (B-1 B cells). The origin of B-1 cells is less clearly under-
produced in the TG mice results in a small reduction in stood, but this population may derive directly from fetal
the numbers of CD4 and CD8 T cells in the spleen or adult precursor populations (Wortis and Berland,
(Figure 3B). We can conclude from our findings that 2001). Analysis of the PEC population isolated from
neither APRIL nor BLyS plays a significant role in devel- BLyS/ mice revealed the most striking difference be-
opment of naive T cells in a preimmune state. tween the BLyS/ mutant mice and TACI-Ig -TG and
The biological effect of APRIL in vitro suggests a role -treated mice. The PEC from BLyS/ mice contained
for this molecule in T cell costimulation (Yu et al., 2000). very few B-2 B cells but had normal levels of B-1 B cells
Analysis of the mature T cell populations in BLyS/ mice compared to WT mice. We have shown previously that
indicates a potential role for BLyS in the development mice overexpressing BLyS as a transgene develop ele-
of memory T cells in the spleen (Table 1). Whether the vated B-1 cells in the spleen (Gross et al., 2000). The
subtle drop in T cell numbers in the TACI-Ig TG or the lack of B-1 cells in mice overexpressing TACI-Ig or in
drop in effector T cells in BLyS/ mice is the result of mice treated with TACI-Ig suggests that another li-
a direct effect of TACI-Ig on the T cells themselves, or gand(s), possibly APRIL, acts in synergy with BLyS to
of an indirect effect stemming from the paucity of B modulate the development of this B cell population and
cells, is not yet clear. Studies on B cell-deficient MT may compensate for BLyS in the development of B-1
mice clearly demonstrate a role for B cells in the genera- cells in the mutant mice.
tion of a T cell response to parasitic and viral infection These experiments indicate that BLyS plays an impor-
(Langhorne et al., 1998; Homann et al., 1998). More ex- tant role in the development of conventional B-2 cells
periments are needed to examine the production of ef- but not in the development of peritoneal B-1 cells. By
fector T cells during antigenic challenge and T cell selec- contrast, TACI-Ig clearly alters the development of both
tion in BLyS-deficient mice or during TACI-Ig treatment B-2 and B-1 B cells (Figures 1 and 3). We have shown
of normal mice. that TACI-Ig treatment can inhibit symptoms of disease
The role of BLyS in B cell activation and humoral in a mouse model of SLE (Gross et al., 2000). Here we
immunity has suggested a utility for TACI-Ig in the treat- demonstrate the ability of TACI-Ig to suppress disease
ment of autoimmune diseases associated with patho- symptoms and the production of pathogenic Abs in CIA.
genic autoantibodies. Here we show that TACI-Ig can In normal mice, we show that TACI-Ig acts as an immu-
inhibit the incidence of disease in a model of CIA either nosuppressive, regulating predominantly B cells without
when administered before onset of disease (7 days prior dramatically affecting other lymphoid or myeloid cell
to the second antigen challenge) or when 52% of the populations. Taken together, the ability of TACI-Ig to
mice have overt signs of inflammation (7 days after the influence the survival of B-2, B-1, and MZ populations
challenge). In both delivery modes, TACI-Ig suppresses and to regulate antigen-specific Ab production in the
the production of anti-collagen Abs that correlate with CIA model underscores the therapeutic utility of this
inhibition of disease progression. Evidence supporting molecule in the treatment of autoimmune disease.
a role for B cells in the development of CIA has been
shown in B cell-deficient MT mice. These mice do not
Experimental Procedures
develop CIA, but their anti-collagen T cell response is
normal (Svensson et al., 1998). Generation of Soluble TACI-Ig and Treatment of Normal Mice
Studies have shown that TACI-Ig treatment can inhibit The TACI-Ig protein was generated by fusing the signal sequence
derived from human tissue plasminogen activator, the extracellularthe production of Abs to T cell-dependent antigens, GC
domain of human TACI (amino acids 1–154) (von Bulow and Bram,formation, high-affinity IgG production, and formation
1997), and a mutated Fc region (Fc4) from the human IgG1 heavyof low-affinity IgM (Yan et al., 2000). In the CIA model,
chain. To create Fc4, amino acid substitutions L234A, L235E, andTACI-Ig was delivered 14 to 21 days after the first dose
G237A were introduced into IgG1 Fc to reduce binding to FcRI,
of priming antigen, after GCs have formed. We can pos- FcRIIa, and FcRIII (Duncan et al., 1988; Wines et al., 2000;
tulate several mechanisms by which TACI-Ig sup- Sondermann et al., 2000), and substitutions A330S and P331S were
presses Ab formation. TACI-Ig may act by inhibiting the introduced to reduce C1q-mediated complement fixation (Tao et
al., 1993; Canfield and Morrison, 1991). Protein was purified fromsurvival of mature B cells, reducing the pool of cells that
supernatants derived from CHO DG44 cells expressing the TACI-Igcan develop into Ab-forming cells. Similarly, TACI-Ig
by Protein A chromotagraphy. BALB/c mice (Charles River Labora-could act directly by inhibiting the differentiation of B
tories, Wilmington, MA) were treated via i.p. injection with 100 gcells into Ab-producing plasma cells. TACI-Ig may act
of TACI-Ig, Hu-Ig (the Fc portion of human IgG1 produced as de-
by inhibiting factors required for the maintenance of GCs scribed for TACI-Ig), or PBS three times/week for 14 days.
(suggested by our experiments) or completely inhibiting
GC formation. Regardless of the mechanism, the data VH/E-TACI-Ig TG Mice
taken together indicate that TACI-Ig is a potent inhibitor A PCR fragment containing the TACI-Ig construct described above
was inserted into the expression vector pKFO24 (Gross et al., 2000)of mature B cells and the production of antigen-specific
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containing the VH/E promoter/enhancer. Fertilized ova from matings rose gel with 2.2 M formaldehyde in PBS and transferred to Nytran
N membrane (Schleicher and Schuell, Keene, NH) in 20X SSC, fol-of B6C3F1Tac mice were microinjected with the transgene insert and
implanted into pseudopregnant females. Founders were identified by lowed by UV cross-linking. A 432 bp probe was amplified by PCR
from a mouse BLyS cDNA using the following oligos: ZC38343,PCR on genomic tail DNA, and TG lines were established by breeding
founders with C57BL/6Tac mice (Taconic, Germantown, NY). 5-GGCAAACAGGCTATTTCTTCAT-3 and ZC38344, 5-TTGGAT
CAGATTCAACGGGT-3. The probe was labeled with [
32P]dCTP
using the Rediprime II DNA Labeling System (Amersham PharmaciaBLyS/ Mice
Biotech, UK). Hybridization was performed in ExpressHyb (ClontechHeterozygous knockout mice were generated at Lexicon Genetics
Laboratories, Palo Alto, CA) for 12 hr at 65C, followed by fourIncorporated (The Woodlands, TX), essentially as previously de-
washes in 2X SCC, 0.05% SDS at 22C and two washes in 0.1Xscribed (Wattler et al., 1999; Matalon et al., 2000). BLyS genomic
SSC, 0.1% SDS at 50C.clones were identified in a KOS genomic library derived from mouse
strain 129S5 (129/SvEvBrd). A 10.5 kb genomic clone was used
to create a replacement-type targeting vector to delete a 334 bp
Cell Staining and Flow Cytometrysequence beginning with codon 2 of exon 1 and extending through
Cell suspensions were incubated on ice for 20 min in the presencethe first 19 bp of intron 1 containing the cytoplasmic and transmem-
of the appropriate FITC-, PE-, CyChrome-, PerCP-, and/or biotin-brane domains of BLyS (Figure 5). This deleted region was replaced
conjugated mAbs in FACS wash buffer (WB, HBSS1%BSA10by an IRES	Gal-PolyA/MC1neo-PolyA selectable marker cassette
mM hepes [pH 7.4]). Cells were washed with 1.5 ml of WB, pelleted,that contains termination codons in all three reading frames, an
and resuspended in WB containing streptavidin (SA)-CyChrome, ifinternal ribosome entry sequence derived from encephalomyocardi-
necessary. After another 20 min incubation on ice, the cells weretis virus fused in-frame to the lacZ gene, a polyA signal, followed
washed and analyzed on a FACScan (Becton Dickinson, Mountainby a neor selectable marker (Thomas and Capecchi, 1987), and a
View, CA). RBC and dead cells were excluded by electronicallysecond pA signal. The targeting vector contained two copies of the
gating data on the basis of FSC versus SSC profiles; a minimum ofnegative selectable marker HSV-tk, one flanking each side of the
2  104 cells of interest were analyzed further.genomic insert. The linerarized targeting vector was electroporated
into 129S5-derived Lex-1 ES cells and subjected to positive/nega-
tive selection with G418 and fialouridine. A total of 22 (11%) targeted
Antibodiesclones were identified by Southern blotting (Figure 5). Chimeras were
Anti-CD3-CyChrome (clone 145-2C11), anti-CD4-PE (clonegenerated by injection of targeted ES cells into C57BL/6-Tyrc-Brd blasto-
H129.19), anti-CD5-PE (clone 53-7.3), anti-CD8
-CyChrome (clonecysts and transplantation into pseudopregnant females. Progeny
53-6.7), anti-CD19-PE (clone 1D3), anti-CD21/35-FITC (clone 7G6),were genotyped by Southern blotting employing probe B (Figure 5) or
anti-CD23-PE (clone B3B4), anti-CD43-FITC (clone S7), anti-CD44-separate PCR reactions detecting the wild-type and neo alleles. Probe
PE (clone IM7), anti-CD45R/B220-PerCP (clone RA3-6B2), anti-B was generated by PCR amplification of a 608 bp product from
CD62L-FITC (clone MEL-14), anti-IgD-FITC (clone 11-26c.2a), anti-genomic clone pKOS/ZG7/66, using the following primers: ZC37420,
IgM-biotin (clone R6-60.2), and SA-CyChrome were purchased from5-CCATCCAGAATGCTCTACTG-3 and ZC37422, 5-CAGCCTTGC
PharMingen (San Diego, CA). Goat anti-mouse IgM-PE was obtainedTTGGCTGCAC-3. PCR genotyping was performed with the primer
from Southern Biotechnology Associates (Birmingham, AL). Rat anti-pairs: ZG37424 (sense wild-type BLyS), 5-CTGCCACCACCGTGC
mouse CD45R/B220-TriColor was purchased from Caltag (Bur-CTCTGTT-3 and ZG37457 (antisense wild-type BLyS), 5-CCGCGG
lingame, CA).CGGCTGGTGTT-3 for a 268 bp amplicon; ZG23131 (sense neo),
5-GGGCGCCCGGTTCTTTTTGTC-3 and ZG23133 (antisense neo),
5-TTCGCCGCCAAGCTCTTCAGC-3 for a 579 bp amplicon.
Serum Ig and Anti-Collagen IgG ELISAs
Total serum Igs were measured according to standard ELISA proto-
CIA Model cols. ELISA microtiter MaxiSorp plates (Nalge/Nunc, Rochester, NY)
Male DBA/1 mice (Jackson Laboratory, Bar Harbor, ME) were in- were coated with 1g/ml goat anti-mouse IgG (Jackson ImmunoRe-
jected with an emulsion of chick collagen type II (Chrondrex, LLC) search, West Grove, PA) or 1 g/ml goat anti-mouse IgM (Zymed,
in Arthrogen-CIA Adjuvant (Complete Freund’s adjuvant [CFA] con- South San Francisco, CA) and incubated overnight at 4C. Plates
taining 1 mg/ml Mycobacterium tubeculosis, H37RA, Difco) on Day were blocked 10 min at room temperature with SuperBlock (Pierce,
–21 s.c. at the base of the tail. On Day 0, the mice were given a Rockford, IL). Diluted serum samples and Ab standards were added
second immunization of collagen emulisified in Incomplete Freund’s and incubated at RT for 2 hr. Bound Igs were detected with horserad-
adjuvant (IFA). All mice were assessed daily beginning on Day 0 by ish peroxidase (HRP)-conjugated goat anti-mouse IgG Fc or HRP-
assigning a clinical score to each of their paws, based on the severity conjugated goat anti-mouse IgM (Jackson ImmunoResearch). HRP
of edema and erythema. Arthritic lesions for each paw were graded activity was measured with o-phenylenediamine dihydrochloride
on a score of 0-3, where 0  normal, 0.5  only toe(s) involved, 1  (OPD) (Pierce), and absorbances were measured on a Spectra MAX
mild edema and erythema in paw, 2  moderate edema and ery- 190 at 490 nm (Molecular Devices Corporation, Sunnyvale, CA). For
thema in paw, and 3  severe edema and erythema in paw. The detection of collagen-specific Abs, MaxiSorp plates were coated
arthritic score for each animal each day was the sum of the clinical overnight at 4C with 5 g/ml chicken collagen (ELCII kit from Chon-
scores for all four paws. Animals were euthanized after 7 consecu- drex). Plates were blocked for 10 min at room temperature in Su-
tive days of a score of 2 or more in any one paw. At necropsy, perBlock. Diluted serum samples were incubated overnight at 4C.
serum, inguinal, and mLN, and paws were collected. Paw histology Peroxidase labeled-goat anti-mouse IgG Fc (ICN/Cappel) was used
was assessed formalin-fixed sections stained with H&E using the to measure collagen-specific total IgG. HRP activity was measured
following scoring system: 0  normal synovial membrane (2–3 cells as described for serum Ig ELISAs. Data are reported as the geomet-
thick), smooth articular surfaces; 1  synovial membrane hypertro- ric mean absorbance (OD490).
phy, cellular infiltrate into synovial space; 2  grade 1, plus synovial
membrane hypertrophy and superficial cartilage erosion; 3  grade
2, plus major erosion of the cartilage and subchondral bone; and 4 TACI-Ig Quantitation Assay
loss of joint integrity through erosion with massive cellular infiltrate. To detect soluble TACI-Ig in the serum of mice, MaxiSorp plates
Each paw was given a score of 0–4, determined by the maximal were coated overnight at 4C with a mouse anti-human TACI mAb
joint score for that paw. generated at ZymoGenetics. Plates were washed and blocked for
10 min with SuperBlock prior to the addition of diluted serum sam-
ples or TACI-Ig standards. After a 2 hr incubation at 37C, the platesNorthern Blot Analysis
RNA was isolated using the RNeasy Midi kit (Qiagen, Valencia, CA) were washed extensively and incubated for 1 hr at 37C with HRP-
conjugated goat anti-human IgG Fc-specific Abs (Jackson Immu-according to the manufacturer’s protocol, with the exception that
a DNase I treatment at 22C for 15 min was included between RW1 noResearch). HRP activity was measured with OPD as a substrate.
Absorbances were measured at 492 nm.washes. 1–2 g poly A RNA was electrophoresed on a 1.5% aga-
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